Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study

This publication has 36 references indexed in Scilit:

• Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
  Drug Metabolism and Disposition, 2009
• Comparison of several testing strategies for combination drug efficacy trials based on the closure principle
  Statistics in Medicine, 2008
• Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen
  British Journal of Clinical Pharmacology, 2006
• Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin
  The Journal of Clinical Pharmacology, 2006
• ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
  Journal of the American College of Cardiology, 2006
• Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice
  International Journal Of Clinical Practice, 2006
• Stroke Severity in Atrial Fibrillation
  Stroke, 1996
• Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)
  The American Journal of Cardiology, 1994
• Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
  Stroke, 1991
• Coronary heart disease and atrial fibrillation: The Framingham Study
  American Heart Journal, 1983